Document is current

Any future updates will be listed below

Fortgeschrittenes HER2-positives Mammakarzinom: Neuzulassung in der Zweitlinie

Crossref DOI link: https://doi.org/10.1007/s15013-022-5074-9

Published Online: 2022-12-07

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark